• sales@syndicatedanalytics.com
  • +1-213-316-7435

GCC Biosimilar Market by molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab and Follitropin Alfa) by Type of Manufacturing (In-House Manufacturing and Contract Manufacturing) and Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency and Female Infertility): Industry Analysis, Trends, Growth and Forecast 2019-2024

Buy Now
Request Sample
Request Brochure
Ask An Analyst


GCC Biosimilar Market Overview:

The GCC biosimilar market was worth US$ XX Billion in 2018, expanding at a CAGR of X% during 2011-2018. The market is projected to register a CAGR of X% during 2019-2024, reaching US$ XX Billion by 2024.The GCC biosimilars market is currently growing at a healthy growth rate. Biosimilars, also known as subsequent entry biologic or follow-on biologic, are generic non-patented chemical and therapeutic equivalents of brand name biopharmaceutical drugs. These drugs are different from generic drugs as they exhibit a high molecular complexity. They possess similar medical properties in terms of potency, safety, and efficacy to original biologic products. Due to the cost-effectiveness and the rising incidence of chronic diseases such as diabetes, cancer, growth hormone deficiency, and anaemia, the demand for biosimilar drugs is increasing in the GCC countries. The introduction of biosimilars has led to improved access to the premium-priced biopharmaceuticals at lesser costs. In addition, the increasing investments in research and development activities coupled with favourable policies to accelerate approvals of biosimilar drugs is also boosting the market growth in the GCC region.

GCC Biosimilar Market Segment Insights:

The report has assessed the GCC biosimilar market on the basis of molecule covering, infliximab, insulin glargine, epoetin alfa, etanercept, filgrastim, somatropin, rituximab and follitropin alfa. The report has further examined the market based on type of manufacturing including, In-house manufacturing and contract manufacturing. On the basis of indication covering, auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency and female infertility. On a regional basis, the report examines the biosimilar market in Saudi Arabia, United Arab Emirates, Qatar, Kuwait, Oman and Bahrain. An evaluation of the competitive landscape has also been provided with the details of the key players operating in the GCC biosimilar market.

Highlights of the GCC Biosimilar Market Report:

  • Historical and current scenario
  • Trends and developments
  • Market forecast
  • Price analysis and forecast
  • Porter’s five forces analysis
  • SWOT analysis
  • Value chain analysis

Key Market Segments:

The GCC biosimilar market has been analysed as followed:

Segmentation by Molecule:

  • Infliximab
  • Insulin Glargine
  • Epoetin Alfa
  • Etanercept
  • Filgrastim
  • Somatropin
  • Rituximab
  • Follitropin Alfa

Segmentation by Type of Manufacturing:

  • In-house Manufacturing
  • Contract Manufacturing

Segmentation by Indication:

  • Auto-Immune Diseases
  • Blood Disorder
  • Diabetes
  • Oncology
  • Growth Deficiency
  • Female Infertility

Segmentation by Country:

  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Kuwait
  • Oman
  • Bahrain

Report Customisation:

The GCC biosimilar market report can be customised as per your requirements. You can get in touch with our analyst, who will make sure that the report suits your research needs

1 Introduction
    1.1    Research Objectives 
    1.2    Stakeholders
    1.3    Scope of the Report
    1.4    Assumptions and Limitations
2 Research Methodology 
    2.1    Data Collection
        2.1.1    Primary Sources
        2.1.2    Secondary Sources
    2.2    Market Size Estimation
        2.2.1    Bottom-Up Approach
        2.2.2    Top-Down Approach
    2.3    Data Validation
3 Executive Summary
4 Introduction to Global Biosimilar Market
    4.1    Overview
    4.2    WHO and FDA Terminology on Biosimilars
    4.3    Biosimilars and Generics
    4.3    Biosimilars and Branded Biological Products
5 Biosimilar Research, Development and Manufacturing
    5.1    Research and Development: Biosimilars vs. Innovator Drugs
    5.2    Manufacturing: Biosimilars vs. Innovator Drugs
6 Global Biosimilar Market
    6.1    Historical Market Trends
    6.2    Market Segmentation by Region
    6.3    Market Outlook
7 GCC Biosimilar Market
    7.1    Industry Overview 
    7.2    Key Industry Developments
    7.3    Market Trends
        7.3.1    Key Market Indicators
        7.3.2    Historical Market Trends
        7.3.3    Market Outlook
8 GCC Biosimilar Market Segmentation by Country
    8.1    Saudi Arabia  
        8.1.1    Historical Market Trends
        8.1.2    Market Outlook
    8.2    United Arab Emirates   
        8.2.1    Historical Market Trends
        8.2.2    Market Outlook
    8.3    Qatar 
        8.3.1    Historical Market Trends
        8.3.2    Market Outlook
    8.4    Kuwait 
        8.4.1    Historical Market Trends
        8.4.2    Market Outlook
    8.5    Oman  
        8.5.1    Historical Market Trends
        8.5.2    Market Outlook
    8.6    Bahrain  
        8.6.1    Historical Market Trends
        8.6.2    Market Outlook
9 GCC Biosimilar Market Segmentation by Module 
    9.1    Infliximab
        9.1.1    Historical Market Trends
        9.1.2    Market Outlook
    9.2    Insulin Glargine
        9.2.1    Historical Market Trends
        9.2.2    Market Outlook
    9.3    Epoetin Alfa
        9.3.1    Historical Market Trends
        9.3.2    Market Outlook
    9.4    Etanercept
        9.4.1    Historical Market Trends
        9.4.2    Market Outlook
    9.5    Filgrastim
        9.5.1    Historical Market Trends
        9.5.2    Market Outlook
    9.6    Somatropin
        9.6.1    Historical Market Trends
        9.6.2    Market Outlook
    9.7    Rituximab
        9.7.1    Historical Market Trends
        9.7.2    Market Outlook
    9.8    Follitropin Alfa
        9.8.1    Historical Market Trends
        9.8.2    Market Outlook
10 GCC Biosimilar Market Segmentation by Type of Manufacturing 
    10.1    In-House Manufacturing
        10.1.1    Historical Market Trends
        10.1.2    Market Outlook
    10.2   Contract Manufacturing
        10.2.1    Historical Market Trends
        10.2.2    Market Outlook
11 GCC Biosimilar Market Segmentation by Indication
    11.1    Auto-Immune Diseases
        11.1.1    Historical Market Trends
        11.1.2    Market Outlook
    11.2    Blood Disorder
        11.2.1    Historical Market Trends
        11.2.2    Market Outlook
    11.3    Diabetes
        11.3.1    Historical Market Trends
        11.3.2    Market Outlook
    11.4    Oncology
        11.4.1    Historical Market Trends
        11.4.2    Market Outlook
    11.5    Growth Deficiency 
        11.5.1    Historical Market Trends
        11.5.2    Market Outlook
    11.6    Female Infertility
        11.6.1    Historical Market Trends
        11.6.2    Market Outlook
12 GCC Biosimilar Industry: Market Dynamics
    12.1   Overview
    12.2   Strengths
    12.3   Weaknesses 
    12.4   Opportunities
    12.5   Threats
13 GCC Biosimilar Industry: Value Chain Analysis
    13.1   Overview
    13.2   Research and Development
    13.3   Raw Material Suppliers
    13.4   Inbound Logistics
    13.5   Production
    13.6   Marketing 
    13.7   Outbound Logistics
    13.8   Consumers 
14 GCC Biosimilar Industry: Porter’s Five Forces Analysis
    14.1   Overview
    14.2   Threat of New Entrants
    14.3   Threat of Substitutes
    14.4   Bargaining Power of Buyers
    14.5   Bargaining Power of Suppliers
    14.6   Intensity of Rivalry
15 Competitive Landscape
    15.1   Market Structure
    15.2   Key Players 
    15.3   Key Success Factors 
16 Key Player Profiles
 
List of Figures

Figure 1: Global: Biosimilar Market: Sales Value (in Million US$), 2011-2018
Figure 2: Global: Biosimilar Market: Segmentation by Region (in %), 2018
Figure 3: Global: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 4: GCC: Biosimilar Market: Sales Value (in Million US$), 2011-2018
Figure 5: GCC: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 6: GCC: Biosimilar Market: Segmentation by Country (in %), 2018
Figure 7: GCC: Biosimilar Market: Segmentation by Molecule (in %), 2018
Figure 8: GCC: Biosimilar Market: Segmentation by Type of Manufacturing (in %), 2018
Figure 9: GCC: Biosimilar Market: Segmentation by Indication (in %), 2018
Figure 10: Saudi Arabia: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 11: Saudi Arabia: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 12: United Arab Emirates: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 13: United Arab Emirates: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 14: Qatar: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 15: Qatar: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 16: Kuwait: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 17: Kuwait: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 18: Oman: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 19: Oman: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 20: Bahrain: Biosimilar Market: Sales Value (in Million US$), 2011 & 2018
Figure 21: Bahrain: Biosimilar Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 22: GCC: Biosimilar (Infliximab) Market: Sales Value (in Million US$), 2011 & 2018
Figure 23: GCC: Biosimilar (Infliximab) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 24: GCC: Biosimilar (Insulin Glargine) Market: Sales Value (in Million US$), 2011 & 2018
Figure 25: GCC: Biosimilar (Insulin Glargine) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 26: GCC: Biosimilar (Epoetin Alfa) Market: Sales Value (in Million US$), 2011 & 2018
Figure 27: GCC: Biosimilar (Epoetin Alfa) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 28: GCC: Biosimilar (Etanercept) Market: Sales Value (in Million US$), 2011 & 2018
Figure 29: GCC: Biosimilar (Etanercept) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 30: GCC: Biosimilar (Filgrastim) Market: Sales Value (in Million US$), 2011 & 2018
Figure 31: GCC: Biosimilar (Filgrastim) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 32: GCC: Biosimilar (Somatropin) Market: Sales Value (in Million US$), 2011 & 2018
Figure 33: GCC: Biosimilar (Somatropin) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 34: GCC: Biosimilar (Rituximab) Market: Sales Value (in Million US$), 2011 & 2018
Figure 35: GCC: Biosimilar (Rituximab) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 36: GCC: Biosimilar (Follitropin Alfa) Market: Sales Value (in Million US$), 2011 & 2018
Figure 37: GCC: Biosimilar (Follitropin Alfa) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 38: GCC: Biosimilar (In-house Manufacturing) Market: Sales Value (in Million US$), 2011 & 2018
Figure 39: GCC: Biosimilar (In-house Manufacturing) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 40: GCC: Biosimilar (Contract Manufacturing) Market: Sales Value (in Million US$), 2011 & 2018
Figure 41: GCC: Biosimilar (Contract Manufacturing) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 42: GCC: Biosimilar (Auto-Immune Diseases) Market: Sales Value (in Million US$), 2011 & 2018
Figure 43: GCC: Biosimilar (Auto-Immune Diseases) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 44: GCC: Biosimilar (Blood Disorder) Market: Sales Value (in Million US$), 2011 & 2018
Figure 45: GCC: Biosimilar (Blood Disorder) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 46: GCC: Biosimilar (Diabetes) Market: Sales Value (in Million US$), 2011 & 2018
Figure 47: GCC: Biosimilar (Diabetes) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 48: GCC: Biosimilar (Oncology) Market: Sales Value (in Million US$), 2011 & 2018
Figure 49: GCC: Biosimilar (Oncology) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 50: GCC: Biosimilar (Growth Deficiency) Market: Sales Value (in Million US$), 2011 & 2018
Figure 51: GCC: Biosimilar (Growth Deficiency) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 52: GCC: Biosimilar (Female Infertility) Market: Sales Value (in Million US$), 2011 & 2018
Figure 53: GCC: Biosimilar (Female Infertility) Market Outlook: Sales Value (in Million US$), 2019-2024
Figure 54: GCC: Biosimilar Industry: Market Dynamics
Figure 55: GCC: Biosimilar Industry: Value Chain Analysis
Figure 56: GCC: Biosimilar Market: Porter’s Five Forces Analysis

List of Tables

Table 1: GCC: Biosimilar Market: Key Industry Highlights, 2018 and 2024
Table 2: GCC: Biosimilar Market Outlook: Segmentation by Country (in Million US$), 2019-2024
Table 3: GCC: Biosimilar Market Outlook: Segmentation by Molecule (in Million US$), 2019-2024
Table 4: GCC: Biosimilar Market Outlook: Segmentation by Type of Manufacturing (in Million US$), 2019-2024
Table 5: GCC: Biosimilar Market Outlook: Segmentation by Indication (in Million US$), 2019-2024
Table 6: GCC: Biosimilar Market Structure
Table 7: GCC: Biosimilar Market: Key Players
 

Special Prices


    Syndicated Analytics provides special pricing for:

  • Academic Institutes
  • Government Agencies
  • Nonprofit Organizations

  • For more information, feel free to contact us.



Request Customization


Related Reports

Onion Powder Prefeasibility Analysis Report 2019

The report offers an in-depth roadmap or setting up a Onion Powder manufacturing plant covering the essential techno-commercial aspects.

Table Salt Prefeasibility Analysis Report 2019

The report offers an in-depth roadmap or setting up a Table Salt manufacturing plant covering the essential techno-commercial aspects.

Sugar Cubes Prefeasibility Analysis Report 2019

The report offers an in-depth roadmap or setting up a Sugar Cubes manufacturing plant covering the essential techno-commercial aspects

Pasta Sauce Prefeasibility Analysis Report 2019

The report offers an in-depth roadmap or setting up a Pasta Sauce manufacturing plant covering the essential techno-commercial aspects.

Garlic Powder Prefeasibility Analysis Report 2019

The report offers an in-depth roadmap or setting up a Garlic Powder manufacturing plant covering the essential techno-commercial aspects.